Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr58.60 SEK
Change Today +1.10 / 1.91%
Volume 3.1M
As of 11:30 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAB) Snapshot

Open
kr58.05
Previous Close
kr57.50
Day High
kr59.20
Day Low
kr56.50
52 Week High
01/26/15 - kr91.20
52 Week Low
08/24/15 - kr50.25
Market Cap
22.4B
Average Volume 10 Days
5.4M
EPS TTM
kr1.47
Shares Outstanding
368.6M
EX-Date
09/2/15
P/E TM
39.9x
Dividend
kr0.50
Dividend Yield
0.85%
Current Stock Chart for ELEKTA AB-B SHS (EKTAB)

Related News

No related news articles were found.

elekta ab-b shs (EKTAB) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAB) Details

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,828 Employees
Last Reported Date: 09/1/15
Founded in 1972

elekta ab-b shs (EKTAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAB) Key Developments

Elekta AB Announces Dividend, Payable on September 8, 2015

Elekta AB announced that a per-share dividend of SEK 0.50 to be distributed to shareholders. The record date for the dividend was set at September 3, 2015 and the payment is expected to be made on September 8, 2015.

Elekta AB Announces Earnings Results for the First Quarter Ended July 2015; Reiterates Sales Guidance for the First Half and Second Half of 2016; Provides Earnings Guidance for Fiscal 2016

Elekta AB announced earnings results for the first quarter ended July 2015. For the quarter, the company’s net sales increased 20% to SEK 2,239 million compared to SEK 1,865 million a year ago. EBITA before non-recurring items amounted to SEK 41 million LBITA before non-recurring items of SEK 38 million a year ago. Net loss amounted to SEK 129 million compared to SEK 137 million a year ago. Loss per share before dilution amounted to SEK 0.34 compared to SEK 0.36 a year ago. Loss per share after dilution amounted to SEK 0.34 million compared to SEK 0.36 a year ago. The company reiterates its outlook and the company expects negative growth in net sales for the first half of 2016, while growth is expected to return during the second half of 2016. The company talked about SEK 100 million negative for the full year of fiscal 2016, which obviously is included in calculation on the EBITA, positive SEK 50 million. On the financial net, it had roughly then SEK 210 million sort of previous year, and it thinks that number is more or less the ballpark that one can calculate for the full year.

Gustave Roussy Chooses Elekta's Versa HD

Gustave Roussy has awarded Elekta with an order for four Versa HD linear accelerators, replacing their existing installed base of competing systems. Gustave Roussy started a program in 2013 to gain a clear leadership in the field of radiotherapy. Acquiring Versa HD will help it achieve its ambition to place innovation at the heart of a human, scientific and technological revolution in the fight against cancer. Versa HD is designed to be the most sophisticated, high-versatility treatment system, giving clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. The order for the Versa HD systems was booked in Elekta's first quarter for the fiscal year 2015-2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAB:SS kr58.60 SEK +1.10

EKTAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $6.66 USD +0.02
Eckert-Ziegler Bebig €1.05 EUR -0.02
Icad Inc $3.92 USD +0.23
MRI Interventions Inc $0.74 USD -0.004
RaySearch Laboratories AB kr113.25 SEK 0.00
View Industry Companies
 

Industry Analysis

EKTAB

Industry Average

Valuation EKTAB Industry Range
Price/Earnings 40.2x
Price/Sales 2.0x
Price/Book 3.3x
Price/Cash Flow 38.8x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.